Overview

A Study of JMT106 Injection in the Treatment of Advanced Solid Tumors

Status:
RECRUITING
Trial end date:
2028-11-15
Target enrollment:
Participant gender:
Summary
This study is the first-in-human Phase I study of JMT106 injection, comprising two phases: Dose escalation with backfill and cohort expansion. The planned study population consists of subjects with advanced solid tumors. The objective is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of JMT106 injection as monotherapy in participants with advanced solid tumors
Phase:
PHASE1
Details
Lead Sponsor:
Shanghai JMT-Bio Inc.